Clinical Trials in a Molecular World

Neuroimaging Clinics of North America

Volumn 16, Issue 4, 2006, Pages 681-694

  Schellingerhout, Dawid ^a   Gelovani, Juri ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; ANDROGEN RECEPTOR; CARBON 11; CASPASE; CETUXIMAB; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE) CU 64; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; FIALURIDINE I 124; FLUORODEOXY LEVO THYMIDINE F 18; FLUORODEOXYGLUCOSE; FLUORODIHYDROXYTESTOSTERONE; GEFITINIB; IMATINIB; LIPOCORTIN 5; METHIONINE C 11; OXYGEN 15; RADIOPHARMACEUTICAL AGENT; THIOSEMICARBAZONE DERIVATIVE; THYMIDINE DERIVATIVE; THYMIDINE KINASE; TRASTUZUMAB;

APOPTOSIS; BRAIN INFARCTION; BREAST CANCER; CANCER CHEMOTHERAPY; CASTRATION; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CARCINOMA; COMBINATION CHEMOTHERAPY; CYCLOTRON; DIAGNOSTIC IMAGING; DIFFUSION COEFFICIENT; DRUG ACCUMULATION; GASTROINTESTINAL STROMAL TUMOR; GENE THERAPY; GLIOMA; HISTOLOGY; HUMAN; HYPOXIA; IMAGE QUALITY; LUNG NON SMALL CELL CANCER; MEDICAL RESEARCH; META ANALYSIS; MOLECULAR IMAGING; MONOTHERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 37849188975     PISSN: 10525149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nic.2006.08.003     Document Type: Review

References (115)

1. Graus-Porta D., Beerli R.R., Daly J.M., et al. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16 7 (1997) 1647-1655
2. Grunwald V., and Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 95 12 (2003) 851-867
3. Herbst R.S. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59 Suppl 2 (2004) 21-26
4. Yarden Y. The EGFR family and its ligands in human cancer: signaling mechanisms and therapeutic opportunities. Eur J Cancer 37 Suppl 4 (2001) S3-S8
5. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 103 2 (2000) 211-225
6. Starling N., and Cunningham D. Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: Present and future directions. Curr Opin Oncol 16 4 (2004) 385-390
7. Arteaga C.L. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 284 1 (2003) 122-130
8. American Cancer Society. Cancer facts and figures: 2005. Available at: www.cancer.org.
9. Slamon D.J., Clark G.M., and Wong S.G. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 4785 (1987) 177-182
10. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 4905 (1989) 707-712
11. Nahta R., and Esteva F.J. Herceptin: mechanisms of action and resistance. Cancer Lett 232 2 (2006) 123-138
12. Shin D.M., Donato N.J., Perez-Soler R., et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 7 5 (2001) 1204-1213
13. Wakeling A.E., Guy S.P., Woodburn J.R., et al. ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62 20 (2002) 5749-5754
14. Fukuoka M., Yanso S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced nonsmall cell lung cancer. J Clin Oncol 21 12 (2003) 2237-2246
15. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with nonsmall cell lung cancer: a randomized trial. JAMA 290 16 (2003) 2149-2158
16. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 21 (2004) 2129-2139
17. Cohen M.H., Williams G.A., Sridhara R., et al. United States Food and Drug Administration Drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 10 4 (2004) 1212-1218
18. Frederick L., Wang X.Y., Eley G., et al. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60 5 (2000) 1383-1387
19. Rich J.N., Reardon D.A., Peery T., et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22 1 (2004) 133-142
20. Maslyar D.J., Jahan T.M., and Jablons D.M. Mechanisms of and potential treatment strategies for metastatic disease in nonsmall cell lung cancer. Semin Thorac Cardiovasc Surg 16 1 (2004) 40-50
21. Shepherd F.A., Pereira J.R., Ciuleanu T., et al. Erlotinib in previously treated nonsmall cell lung cancer. N Engl J Med 353 2 (2005) 123-132
22. Perez-Soler R., Chachoua A., Hammond L.A., et al. Determinants of tumor response and survival with erlotinib in patients with nonsmall cell lung cancer. J Clin Oncol 22 16 (2004) 3238-3247
23. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 11 (2001) 783-792
24. Esteva F.J., Valero V., Booser D., et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20 7 (2002) 1800-1808
25. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer. N Engl J Med 351 4 (2004) 337-345
26. Jacobs A.H., Voges J., Kracht L.W., et al. Imaging in gene therapy of patients with glioma. J Neurooncol 65 3 (2003) 291-305
27. Harsh G.R., Deisboeck T.S., Louis D.N., et al. Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: A gene-marking and neuropathological study. J Neurosurg 92 5 (2000) 804-811
28. Jacobs A., Voges J., Reszka R., et al. Positron emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet 358 9283 (2001) 727-729
29. Osborne C.K. Tamoxifen in the treatment of breast cancer. N Engl J Med 339 22 (1998) 1609-1618
30. Linden H.M., Stekhova S.A., Link J.M., et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 24 18 (2006) 2793-2799
31. Huggins C., and Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
32. Buchanan G., Irvine R.A., Coetzee G.A., et al. Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev 20 3-4 (2001) 207-223
33. Loblaw D.A., Mendelson D.S., Talcott J.A., et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 22 14 (2004) 2927-2941
34. Dehdashti F., Picus J., Michalski J.M., et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 32 3 (2005) 344-350
35. Akabani G., Carlin S., Welsh P., et al. In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. Nucl Med Biol 33 3 (2006) 333-347
36. Socinski M.A., Stinchcombe T.E., Hayes D.N., et al. The emergence of a unique population in nonsmall cell lung cancer: systemic or loco-regional relapse following postoperative adjuvant platinum-based chemotherapy. Semin Oncol 33 Suppl 1 (2006) S32-S38
37. Reardon D.A., and Wen P.Y. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist 11 2 (2006) 152-164
38. Velikyan I., Sundberg A.L., Lindhe O., et al. Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med 46 11 (2005) 1881-1888
39. Babaei M.H., Almqvist Y., Orlova A., et al. [99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: preparation and pre-clinical evaluation. Oncol Rep 13 6 (2005) 1169-1175
40. Calderon Sanchez O., Zayas Crespo F., Leyva Montana R., et al. Direct and indirect labeling with 99mTc of an antireceptor monoclonal antibody of EGF. Rev Esp Med Nucl 24 1 (2005) 38-44
41. Shaul M., Abourbeh G., Jacobson O., et al. Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer. Bioorg Med Chem 12 13 (2004) 3421-3429
42. Mishani E., Abourbeh G., Rozen Y., et al. Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: Potential PET bioprobes for molecular imaging of EGFR-positive tumors. Nucl Med Biol 31 4 (2004) 469-476
43. Wen X., Wu Q.P., Lu Y., et al. Poly(ethylene glycol)-conjugated anti-EGF receptor antibody C225 with radiometal chelator attached to the termini of polymer chains. Bioconjug Chem 12 4 (2001) 545-553
44. Wen X., Wu Q.P., Ke S., et al. Conjugation with 111In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225. J Nucl Med 42 10 (2001) 1530-1537
45. Wang J., Chen P., Su Z.F., et al. Amplified delivery of indium-111 to EGFR-positive human breast cancer cells. Nucl Med Biol 28 8 (2001) 895-902
46. Bonasera T.A., Ortu G., Rozen Y., et al. Potential 18F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase. Nucl Med Biol 28 4 (2001) 359-374
47. Campa M.J., Kuan C.T., O'Connor-Mccourt M.D., et al. Design of a novel small peptide targeted against a tumor-specific receptor. Biochem Biophys Res Commun 275 2 (2000) 631-636
48. Reilly R.M., Kiarash R., Sandhu J., et al. A comparison of EGF and MAB 528 labeled with 111In for imaging human breast cancer. J Nucl Med 41 5 (2000) 903-911
49. Fredriksson A., Johnstrom P., Thorell J.O., et al. In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants. Life Sci 65 2 (1999) 165-174
50. Ramos-Suzarte M., Rodriguez N., Oliva J.P., et al. 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy. J Nucl Med 40 5 (1999) 768-775
51. Kurihara A., Deguchi Y., and Pardridge W.M. Epidermal growth factor radiopharmaceuticals: 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors. Bioconjug Chem 10 3 (1999) 502-511
52. Deguchi Y., Kurihara A., and Pardridge W.M. Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. Bioconjug Chem 10 1 (1999) 32-37
53. Carlsson J., Blomquist E., Gedda L., et al. Conjugate chemistry and cellular processing of EGF-dextran. Acta Oncol (Madr) 38 3 (1999) 313-321
54. Iznaga-Escobar N., Arocha L.A.T., Morales A.M., et al. Technetium-99m-antiepidermal growth factor-receptor antibody in patients with tumors of epithelial origin: Part II. Pharmacokinetics and clearances. J Nucl Med 39 11 (1998) 1918-1927
55. Goldenberg A., Masui H., Divgi C., et al. Imaging of human tumor xenografts with an Indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody. J Natl Cancer Inst 81 21 (1989) 1616-1625
56. Saga T., Endo K., Akiyama T., et al. Scintigraphic detection of overexpressed c-erbB-2 proto-oncogene products by a class-switched murine anti-c-erbB-2 protein monoclonal antibody. Cancer Res 51 3 (1991) 990-994
57. Cuartero-Plaza A., Martinez-Miralles E., Rosell R., et al. Radiolocalization of squamous lung carcinoma with 131I-labeled epidermal growth factor. Clin Cancer Res 2 1 (1996) 13-20
58. Reist C.J., Garg P.K., Alston K.L., et al. Radioiodination of internalizing monoclonal antibodies using N- succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res 56 21 (1996) 4970-4977
59. Rusckowski M., Qu T., Chang F., et al. Technetium-99m labeled epidermal growth factor-tumor imaging in mice. J Pept Res 50 5 (1997) 393-401
60. Morales A.A., Zayas Crespo F., Nunez Gandolff G., et al. Technetium-99m direct radiolabeling of monoclonal antibody ior egf/r3. Nucl Med Biol 25 1 (1998) 25-30
61. Glekas A., Pal A., Doubrovin M., et al. Molecular imaging of EGFR kinase activity in tumors with 124-I-labeled small molecular tracer and PET. Mol Imaging Biol (2006) in press
62. Steffen A.C., Wikman M., Tolmachev V., et al. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Biother Radiopharm 20 3 (2005) 239-248
63. Olafsen T., Kenanova V.E., Sundaresan G., et al. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res 65 13 (2005) 5907-5916
64. Tang Y., Scollard D., Chen P., et al. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [99mTc]-HYNIC-trastuzumab (Herceptin) Fab fragments. Nucl Med Commun 26 5 (2005) 427-432
65. Tang Y., Wang J., Scollard D.A., et al. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using 111In-trastuzumab (Herceptin) Fab fragments. Nucl Med Biol 32 1 (2005) 51-58
66. Robinson M.K., Doss M., Shaller C., et al. Quantitative immuno-positron emission tomography imaging of HER2-positlve tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 65 4 (2005) 1471-1478
67. Perik P.J., Lub-De Hooge M.N., Gietema J.A., et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 24 15 (2006) 2276-2282
68. Jacobs A.H., Kracht L.W., Gossmann A., et al. Imaging in neurooncology. NeuroRx 2 2 (2005) 333-347
69. Jacobs A.H., Thomas A., Kracht L.W., et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 46 12 (2005) 1948-1958
70. Kracht L.W., Friese M., Herholz K., et al. Methyl-[11C]-L-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 30 6 (2003) 868-873
71. Galldiks N., Kracht L.W., Burghaus L., et al. Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging 33 5 (2006) 516-524
72. Uhl M., Weiler M., Wick W., et al. Migratory neural stem cells for improved thymidine kinase-based gene therapy of malignant gliomas. Biochem Biophys Res Commun 328 1 (2005) 125-129
73. Reszka R.C., Jacobs A., and Voges J. Liposome-mediated suicide gene therapy in humans. Methods in Enzymology 391 (2005) 200-208
74. Voges J., Reszka R., Gossmann A., et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol 54 4 (2003) 479-487
75. Jacobs A.H., Winkeler A., Dittmar C., et al. Positron emission tomography monitoring of antiglioblastoma HSV-1-tk gene therapy. Gene Therapy and Regulation 2 1 (2003) 49-57
76. Jacobs A., and Heiss W.D. Towards non-invasive imaging of HSV-1 vector-mediated gene expression by positron emission tomography. Vet Microbiol 86 1-2 (2002) 27-36
77. McGuire A.H., Dehdashti F., Siegel B.A., et al. Positron tomographic assessment of 16-[18F] fluoro-17-estradiol uptake in metastatic breast carcinoma. J Nucl Med 32 8 (1991) 1526-1531
78. Mintun M.A., Welch M.J., Siegel B.A., et al. Breast cancer: PET imaging of estrogen receptors. Radiology 169 1 (1988) 45-48
79. Dehdashti F., Mortimer J.E., Siegel B.A., et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 36 10 (1995) 1766-1774
80. Mortimer J.E., Dehdashti F., Siegel B.A., et al. Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose and 16-[18F]fluoro-17-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 2 6 (1996) 933-939
81. Bonasera T.A., O'Neil J.P., Xu M., et al. Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons. J Nucl Med 37 6 (1996) 1009-1015
82. Larson S.M., Morris M., Gunther I., et al. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. Journal of nuclear medicine: official publication. Journal of Nuclear Medicine 45 3 (2004) 366-373
83. Hammond L.A., Denis L., Salman U., et al. Positron emission tomography (PET): expanding the horizons of oncology drug development. Invest New Drugs 21 3 (2003) 309-340
84. Stroobants S., Goeminne J., Seegers M., et al. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39 14 (2003) 2012-2020
85. Reddy M.P., Reddy P., and Lilien D.L. F-18 FDG PET imaging in gastrointestinal stromal tumor. Clin Nucl Med 28 8 (2003) 677-679
86. Van den Abbeele A.D., and Badawi R.D. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 38 Suppl 5 (2002) S60-S65
87. Joensuu H. Treatment of inoperable gastrointestinal stromal tumor (GIST) with imatinib (Glivec, Gleevec). Med Klin (Munich) 97 Suppl 1 (2002) 28-30
88. Buck A.K., Schirrmeister H., Mattfeldt T., et al. Biological characterisation of breast cancer by means of PET. Eur J Nucl Med Mol Imaging 31 Suppl 1 (2004) S80-S87
89. Buck A.K., Halter G., Schirrmeister H., et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 44 9 (2003) 1426-1431
90. Buck A.K., Schirrmeister H., Hetzel M., et al. 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 62 12 (2002) 3331-3334
91. Chen W., Cloughesy T., Kamdar N., et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 46 6 (2005) 945-952
92. Dekker B., Keen H., Lyons S., et al. MBP-annexin V radiolabeled directly with iodine-124 can be used to image apoptosis in vivo using PET. Nucl Med Biol 32 3 (2005) 241-252
93. Dekker B., Keen H., Shaw D., et al. Functional comparison of annexin V analogues labeled indirectly and directly with iodine-124. Nucl Med Biol 32 4 (2005) 403-413
94. Dicker D.T., Kim S.H., Jin Z., et al. Heterogeneity in non-invasive detection of apoptosis among human tumor cell lines using annexin-V tagged with EGFP or Qdot-705. Cancer Biol Ther 4 9 (2005) 1014-1017
95. Haas R.L.M., De Jong D., Valdes Olmos R.A., et al. In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. Int J Radiat Oncol Biol Phys 59 3 (2004) 782-787
96. Johnson L.L., Schofield L., Donahay T., et al. 99mTc-annexin V imaging for in vivo detection of atherosclerotic lesions in porcine coronary arteries. J Nucl Med 46 7 (2005) 1186-1193
97. Kartachova M., Haas R.L.M., Valdes Olmos R.A., et al. In vivo imaging of apoptosis by 99mTc-annexin V scintigraphy: visual analysis in relation to treatment response. Radiother Oncol 72 3 (2004) 333-339
98. Keen H.G., Dekker B.A., Disley L., et al. Imaging apoptosis in vivo using 124I-annexin V and PET. Nucl Med Biol 32 4 (2005) 395-402
99. Lan X.L., and Zhang Y.X. Preparation of 99mTc-HYNIC-annexin V. Nuclear Science and Techniques/Hewuli 16 5 (2005) 299-303
100. Sarda-Mantel L., Michel J.B., Rouzet F., et al. 99mTc-annexin V and 111In-antimyosin antibody uptake in experimental myocardial infarction in rats. Eur J Nucl Med Mol Imaging 33 3 (2006) 239-245
101. Tait J.F., Smith C., and Blankenberg F.G. Structural requirements for in vivo detection of cell death with 99mTc-annexin V. J Nucl Med 46 5 (2005) 807-815
102. Takei T., Kuge Y., Zhao S., et al. Time course of apoptotic tumor response after a single dose of chemotherapy: comparison with 99mTc-annexin V uptake and histologic findings in an experimental model. J Nucl Med 45 12 (2004) 2083-2087
103. Toretsky J., Levenson A., Weinberg I.N., et al. Preparation of F-18 labeled annexin V: a potential PET radiopharmaceutical for imaging cell death. Nucl Med Biol 31 6 (2004) 747-752
104. Vanderheyden J.L., Liu G., He J., et al. Evaluation of 99mTc-MAG3-annexin V: influence of the chelate on in vitro and in vivo properties in mice. Nucl Med Biol 33 1 (2006) 135-144
105. Watanabe H., Murata Y., Miura M., et al. In vivo visualization of radiation-induced apoptosis using (125)I-annexin V. Nucl Med Commun 27 1 (2006) 81-89
106. Yagle K.J., Eary J.F., Tait J.F., et al. Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med 46 4 (2005) 658-666
107. Lahorte C.M.M., Vanderheyden J.L., Steinmetz N., et al. Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur J Nucl Med Mol Imaging 31 6 (2004) 887-919
108. Uhl M., Saueressig U., van Buiren M., et al. Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging. Invest Radiol 41 8 (2006) 618-623
109. Huang Z., Haider M.A., Kraft S., et al. Magnetic resonance imaging correlated with the histopathological effect of Pd-bacteriopheophorbide (Tookad) photodynamic therapy on the normal canine prostate gland. Lasers Surg Med 38 7 (2006) 672-681
110. Tomura N., Narita K., Izumi J., et al. Diffusion changes in a tumor and peritumoral tissue after stereotactic irradiation for brain tumors: possible prediction of treatment response. J Comput Assist Tomogr 30 3 (2006) 496-500
111. Babsky A.M., Hekmatyar S.K., Zhang H., et al. Predicting and monitoring response to chemotherapy by 1,3-bis(2-chloroethyl)-1-nitrosourea in subcutaneously implanted 9L glioma using the apparent diffusion coefficient of water and (23)Na MRI. J Magn Reson Imaging 24 1 (2006) 132-139
112. Bruehlmeier M., Roelcke U., Schubiger P.A., et al. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. J Nucl Med 45 11 (2004) 1851-1859
113. Myerson R.J., Singh A.K., Bigott H.M., et al. Monitoring the effect of mild hyperthermia on tumour hypoxia by Cu-ATSM PET scanning. Int J Hyperthermia 22 2 (2006) 93-115
114. Yuan H., Schroeder T., Bowsher J.E., et al. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 47 6 (2006) 989-998
115. Obata A., Kasamatsu S., Lewis J.S., et al. Basic characterization of 64Cu-ATSM as a radiotherapy agent. Nucl Med Biol 32 1 (2005) 21-28